Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risedronate
- Development stage
- Approved
- Lead developer
- Procter & Gamble
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Risedronate is a third-generation bisphosphonate used to prevent and treat osteoporosis in postmenopausal women, men with osteoporosis, and individuals (both men and women) taking long-term corticosteroids that may cause bone loss. It is also indicated for the treatment of Paget's disease of bone. Risedronate works by binding to hydroxyapatite in bone tissue and inhibiting farnesyl pyrophosphate synthase within osteoclasts—the cells responsible for bone resorption—thereby reducing their activity and inducing apoptosis. This action slows down the breakdown of bone, increases bone mineral density (BMD), strengthens bones, and reduces the risk of fractures. Original developer: Sanofi/Aventis Manufacturers: Sanofi, Takeda
- Brand names
- ActonelAtelviaActonel with Calcium
- Other names
- risedronic acid
02
Targets
FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on risedronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risedronate.